TG-Costar™
Injection

TG-Costar™ (Tigecycline 50mg) is a next-generation glycylcycline antibiotic injection designed to treat severe and complicated infections like cSSSIs, cIAI, and community-acquired pneumonia. It offers superior action against resistant pathogens including MRSA, VRE, and ESBL, with enhanced protein binding for increased effectiveness. Clinically proven to deliver faster recovery and higher cure rates.

Category: Anti-Infective

Description

Description

Product Description:

TG-Costar™ Injection by Calygen Pharma is a high-efficacy, broad-spectrum antibiotic formulated with Tigecycline 50mg, a first-in-class glycylcycline known for its potent action against multidrug-resistant bacteria. It is especially effective for treating:

Complicated Skin and Skin Structure Infections (cSSSIs)
Complicated Intra-abdominal Infections (cIAI)
Community Acquired Pneumonia

TG-Costar™ binds strongly to proteins, enhancing its performance over traditional tetracyclines. It demonstrates high antimicrobial activity against tough pathogens like MRSA, VRE, and ESBL-producing organisms, making it a critical choice for healthcare providers facing resistant infections.

Key Features:

First Glycylcycline used in the treatment of cSSSIs (complicated skin and skin structure infections)
Best-in-Class Supercharged Antioxidant
Broad-Spectrum Activity: Active against resistant strains:
- MRSA* (Methicillin-resistant Staphylococcus aureus)
- VRE* (Vancomycin-resistant Enterococci)
- ESBL* (Extended-spectrum beta-lactamases)
High protein binding—superior to other tetracyclines